![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Former Indivor Executive Seeks FDA Hearing to Avoid Debarment
Former Indivor Executive Seeks FDA Hearing to Avoid Debarment
![FDA logo blue](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Blue.gif?t=1614197109&width=430)
April 12, 2021
Former Indivior executive Timothy Baxter, who pleaded guilty to spreading false and misleading information about the company’s opioid addiction drug Suboxone, is challenging an FDA proposal to debar him from the industry for five years.
Baxter was sentenced to six months home detention in December and fined $100,000 after admitting that he failed to prevent the company from sending false child safety information to Massachusetts’ Medicaid program regarding Suboxone film.
Baxter’s attorneys are now seeking a hearing with the agency to dispute “issues of material fact,” they believe are relevant to the debarment proposal.
Upcoming Events
-
21Oct